Avastin to become new standard for HER2 MBC
Based on the US Food and Drug Administration's recent accelerated approval of Roche's Avastin (bevacizumab) in the treatment of HER2-negative metastatic breast cancer plus paclitaxel, oncologists will more than double their use of the drug as both a first- and second-line therapy, according to a survey conducted by USA-based GfK Market Measures.
The FDA's decision in February (Marketletter March 3) surprised industry observers as last year its Oncologic Drugs Advisory Committee voted five to four against approving the combination, arguing that the benefits did not outweigh the risks of toxicity (Marketletter December 10, 2007).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze